Akonni Biosystems Licenses USAMRIID IP to Develop Molecular Tests for Biothreat Agents
February 10, 2011
Akonni Biosystems Licenses USAMRIID IP to Develop Molecular Tests for Biothreat Agents
The agreement provides Akonni access to nucleic acid sequences, primers, and probes for several important biothreat agents, which it will incorporate into molecular tests on its TruArray and TruSentry platforms.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Akonni, Wadsworth Center Developing PCR Arrays for Viral Encephalitis, Meningitis
August 10, 2011 / PCR Insider - Akonni Biosystems Partners with Seegene to Develop POC Respiratory Disease Tests
May 10, 2011 / BioArray News - Akonni Licenses Biological Threat Materials from USAMRIID to Develop Tests
February 9, 2011 / GenomeWeb Daily News - Akonni Wins $435K SBIR Grant to Develop POC Tuberculosis Dx on PCR Array Technology
July 29, 2010 / PCR Insider - Dx Focus: Akonni TruDiagnosis Studies; Spartan Bio CYP2C19 Test; Mitomics Prostate Cancer Assay
January 10, 2013 / PCR Insider